Bladder Carcinoma Data with Clinical Risk Factors and Molecular Markers: A Cluster Analysis

Table 4

Clinical and molecular characteristics of the different clusters.

Attribute	Cluster 1	Cluster 2	Cluster 3	Cluster 4
Age^*	61 years; 18	67 years; 9	70 years; 9	82 years; 9
	(23–73)	(52–79)	(60–82)	(72–93)
Multiplicity	No: 100%	No: 20%	No: 40%	No: 50%
	Yes 0%	Yes 80%	Yes 60%	Yes 50%
TM > 3 cm	No: 71%	No: 50%	No: 60%	No: 0%
	Yes: 29%	Yes: 50%	Yes: 40%	Yes: 100%
Grade	G1: 83.3%	G1: 0%	G1: 20%	G1: 0%
	G2: 16.6%	G2: 62.5%	G2: 80%	G2: 50%
	G3: 0%	G3: 37.5%	G3: 0%	G3: 50%
TNM	Ta: 100%	Ta: 0%	Ta: 80%	Ta: 0%
	T1: 0%	T1: 100%	T1: 20%	T1: 100%
Risk group [26]	Low-Int: 100%	Low-Int: 0%	Low-Int: 80%	Low-Int: 0%
	High: 0%	High: 100%	High: 20%	High: 100%
Risk group [38]	Low-Int: 100%	Low-Int: 12.5%	Low-Int: 100%	Low-Int: 0%
	High: 0%	High: 87.5%	High: 20%	High: 100%
p53 (ng/mL)^*	0.1; 0.2	0.5; 1.2	0; 0	0; 0
	(0–0.6)	(0–3.40)	(0-0)	(0-0)
neu (HNU/mL)^*	748.5; 415.6	775.4; 544.2	1379.9; 184.7	854.4; 497.7
	(328–1596.1)	(76–1749.1)	(1253.0–1698.1)	(330.9–1527.2)
EGRF (fmol/mg)^*	6.9; 4.0	12.5; 12.8	8.5; 4.7	22.8; 17.2
	(0.2–11.4)	(2.2–16.6)	(3.0–15.1)	(7.1–39.5)
GS (months)^*	104; 37 (47–128)	93; 46 (3–135)	84; 47 (23–133)	17; 10 (5–28)
RFS (months)^*	104; 37 (47–128)	81; 56 (3–135)	9; 4 (4–13)	13; 10 (5–27)
PFS (months)^*	104; 37 (47–128)	93; 46 (3–135)	84; 47 (23–133)	13; 10 (5–27)

Mean; SD (range).